Accumulating evidence has demonstrated the implication of ACE2 in the pathological progression in tissue injury and several chronic diseases.[12, 13, 14, 15] The quantification of ACE2 distribution and expression level is of importance for the risk profile of COVID‐19—may play a role in monitoring therapies—with potential value in monitoring of the recovered, many of whom display long‐term sequelae including muscle weakness, cognitive, and respiratory issues.[59, 60, 61, 62]. The gene discussed is ACE2; the disease is COVID-19.